LTRN — Lantern Pharma Income Statement
0.000.00%
- $47.45m
- $9.09m
- 43
- 29
- 85
- 51
Annual income statement for Lantern Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2.43 | 5.91 | 12.5 | 14.4 | 17.9 |
Operating Profit | -2.43 | -5.91 | -12.5 | -14.4 | -17.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.43 | -5.91 | -12.4 | -14.3 | -16 |
Net Income After Taxes | -2.43 | -5.91 | -12.4 | -14.3 | -16 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.43 | -5.91 | -12.4 | -14.3 | -16 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.43 | -5.91 | -12.4 | -14.3 | -16 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.403 | -0.95 | -1.14 | -1.31 | -1.47 |
Dividends per Share |